A5027316831- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Nutrition and Health in Aging
- Chronic Lymphocytic Leukemia Research
- Economic and Financial Impacts of Cancer
- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- Healthcare Policy and Management
- Immune Cell Function and Interaction
- Integrated Circuits and Semiconductor Failure Analysis
- Ovarian cancer diagnosis and treatment
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Acute Lymphoblastic Leukemia research
- Biosimilars and Bioanalytical Methods
- Viral-associated cancers and disorders
- Statistical Methods in Clinical Trials
- Global trade and economics
- Pharmaceutical Economics and Policy
- Frailty in Older Adults
- Innovation Policy and R&D
- Respiratory viral infections research
- Child Nutrition and Feeding Issues
- Heart Failure Treatment and Management
- Cancer Immunotherapy and Biomarkers
Kite (United States)
2022-2023
Ibero American University
2022
Philips (Finland)
2017
Precision for Medicine (United States)
2014
Precision Research (United States)
2012
Anderson University - South Carolina
2011
Federal Reserve Bank of Minneapolis
2009
University of Minnesota
2009
National Bureau of Economic Research
2009
Twin Cities Orthopedics
2009
In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients. Here, outcomes from are compared with international SCHOLAR-5 cohort, which applied key trial eligibility criteria simulating randomized controlled conditions. data were extracted institutions 5 countries, and 1 historical clinical for r/r FL patients who...
Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from pivotal randomized phase 3 ZUMA-7 study axicabtagene ciloleucel (axi-cel) SOC. PRO instruments were administered at baseline, day 50, 100, 150, month 9, and every months randomization until 24 or an event-free survival event. The quality life (QoL) set comprised...
Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis ≥65 years in ZUMA-7.
Background: The burden imposed by disease‐associated malnutrition (DAM) on patients and the healthcare system in food‐abundant industrialized countries is often underappreciated. This study measured economic of community‐based DAM United States. Methods: was quantified terms direct medical costs, quality‐adjusted life years lost, mortality across 8 diseases (breast cancer, chronic obstructive pulmonary disease [COPD], colorectal cancer [CRC], coronary heart [CHD], dementia, depression,...
We examined whether a high-dose inactivated influenza vaccine was more efficacious in preventing hospitalizations than standard-dose the Veterans Health Administration (VHA) senior population. This study estimated relative effectiveness (rVE) of high dose versus standard using retrospective cohort VHA patients 65 years age or older 2015–2016 season. To adjust for measured confounders, we matched each recipient with up to 4 recipients vaccinated at same location within 2-week period and...
Affecting an estimated 12.6 million people and causing over 100,000 deaths per year, chronic obstructive pulmonary disease (COPD) exacts a heavy burden on American society. Despite knowledge of the impact COPD morbidity, mortality, health care costs, little is known about association with economic outcomes such as employment collection disability. We quantify Americans aged 51 older—in particular, their prospects likelihood collecting federal disability benefits—by conducting longitudinal...
Diabetic kidney disease (DKD) is a frequent complication of diabetes with potentially devastating consequences that may be prevented or delayed. This study aimed to estimate the health and economic benefit earlier diagnosis treatment DKD.
To assess from a US payer perspective the cost-effectiveness of chimeric antigen receptor T (CAR T)-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) following ≥2 systemic therapy lines.A three-state (i.e. pre-progression, post-progression, death) partitioned survival model was used estimate quality-adjusted life-years (QALYs) costs for patients on each treatment over lifetime horizon....
Axicabtagene ciloleucel (axi-cel) was found to have superior clinical outcomes compared standard of care (SOC; salvage chemoimmunotherapy, followed by high-dose therapy with autologous stem cell rescue for responders) second-line large B-cell lymphoma (2L LBCL) in the pivotal ZUMA-7 trial. The aim this analysis evaluate cost effectiveness using axi-cel current 2L LBCL therapy. A 3-state partitioned-survival model estimated and budget impact from a payer perspective United States. Clinical...
The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular lymphoma (FL) patients on 3rd line (LoT) or higher, for whom existing data are limited. is a retrospective cohort using from adults (≥ 18 years) with grade 1-3a FL, initiating ≥3rd LoT after June 2014 at major centers in the US Europe. Objective response rate (ORR), complete (CR), progression-free survival (PFS) overall (OS) were analyzed by LoT. Time-to-event assessed Kaplan-Meier methods. Of 128 patients,...
Health insurance gives people living with HIV/AIDS access to medical care, including antiretroviral therapy, which in turn can dramatically improve health and reduce the risk of HIV transmission. Yet many remain uninsured. The Affordable Care Act (ACA) seeks decrease number uninsured Americans part by extending Medicaid coverage individuals incomes up 138 percent federal poverty level. However, states are not moving forward this expansion. Using national surveillance data from National...
Observational studies of the relative effectiveness influenza vaccines are essential for public health decision making. Their estimates, however, subject to bias due unmeasured confounders. Instrumental variable (IV) methods can control observed and unobserved confounders.We used linked electronic medical record databases in Veterans Health Administration (VHA) as well Medicare administrative files examine vaccine (rVE) high-dose (HD) versus standard-dose (SD) preventing hospitalizations...
Standard techniques of cost effectiveness analysis measure a technology's benefits in terms expected life years (or quality-adjusted years) gained at today's expectancies. However, this approach ignores the gains which derive from possibility that health technology allows an individual to survive long enough benefit other technological innovations raise expectancy (and quality life) future. Borrowing term finance literature, we refer source value as "option value" innovation. We explain...
Nutrition deficiency is common among hospitalized children. Although oral nutrition supplements (ONS) may improve malnutrition in this population, the benefits and healthcare costs associated with their use have not yet been fully explored. The objective of study was to assess effect ONS on inpatient length stay (LOS) episode cost children.Retrospective analysis 557,348 hospitalizations children aged 2-8 years Premier Research Database. LOS a propensity score- matched sample estimated...
Chimeric antigen receptor T-cell (CAR T) therapy offers a potentially curative option for patients with relapsed and refractory hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Patient-reported experiences CAR T are limited have not been well characterized. The purpose of this qualitative study was to explore patient descriptions key domains health-related quality life (HRQoL) in DLBCL treated therapy.A targeted literature review initially conducted inform the...
Cost-effectiveness data on chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory large B lymphoma (R/R LBCL), accounting inpatient/outpatient site of care (site), are sparse. This payer model compares lifetime costs/benefits CAR cell-treated (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tisagenlecleucel [tisa-cel]) patients with R/R LBCL in the USA. Three-month post-infusion costs were derived from unit and real-world all-payer (RW) site-specific...
Disease-associated malnutrition (DAM) is a well-recognized problem in many countries, but the extent of its burden on Chinese population unclear. This article reports results burden-of-illness study DAM 15 diseases China. Using data from World Health Organization (WHO), China and Nutrition Survey, published literature, mortality disability-adjusted life years (DALYs) lost because were calculated; financial value this was calculated following WHO guidelines. DALYs annually to varied across...
Objective:To determine the association between inhaled corticosteroid (ICS) use and risk of pneumonia among Medicare patients with chronic obstructive pulmonary disease (COPD).Methods:A nested case control analysis was performed to study relationship ICS in a cohort Advantage members COPD. Patients were identified through medical pharmacy claims database. A designated as patient's first inpatient or outpatient episode. Cases matched controls who entered COPD at same time, but had not yet...
Objective: Determine workplace productivity losses attributable to breast cancer progression. Methods: Longitudinal analysis linking 2005 2012 medical and pharmacy claims absence data in the US patients were commercially insured women aged 18 64 diagnosed with cancer. Productivity was measured as employment status total quarterly hours missed, valued using average wages. Results: Six thousand four hundred nine included. Breast progression associated a lower probability of (hazard ratio [HR]...
Surgeons increasingly use robot-assisted minimally invasive surgery for a variety of medical conditions. For hospitals, the acquisition and maintenance robot requires significant investment, but financial returns are not linked to any improvement in long-term patient outcomes current reimbursement environment. Kidney cancer provides useful case study evaluating value that this innovation can provide. is generally treated through partial or radical nephrectomy, with evidence favoring former...
This study evaluated from a US payer perspective the cost-effectiveness of two chimeric antigen receptor T (CAR T) cell therapies, axicabtagene ciloleucel (axi-cel) versus lisocabtagene maraleucel (liso-cel), for treatment adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) following more systemic therapy lines.We developed 3-state (i.e., pre-progression, post-progression, death) partitioned survival model to estimate patients' lifetime outcomes. Mixture cure models...